Conference abstract · 21 Feb 2022
Conference abstractPublished 9 Feb 2022
Targeted and optimized brain drug delivery
CEO Neosinus Health, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
As noted by the World Health Organization, neurological and psychiatric disorders represent the greatest global economic and health burden, where more than 1 billion people are affected and the number is rapidly growing because of the global pandemic. Even though this medical demand has been known for decades, the clinical development pipelines from the pharmaceutical industry are largely deficient, where the most recent commercialized drug for depression was approved by the FDA after three decades of effort by the entire pharmaceutical industry. The lack of clinical advancements is not a strategic failure, but rather a direct result of well-known physiological impedance to drug delivery such as the first-pass effect and the blood-brain-barrier, which either produce significant side effects and/or prevent drugs from reaching the therapeutic target. Thankfully, researchers have discovered viable therapeutic pathways to bypass drug delivery barriers and advancements in nanomedicine will further enable drug delivery, but the greatest potential resides in emerging non-invasive medical device innovations that will provide both targeted and fully optimized drug delivery. This keynote presentation will provide a view into the evolution of drug delivery, clinical dynamics that are motivating emerging classes of therapeutics, existing barriers that could impede advancements and the latest developments that represent great potential for global health transformation. Specific examples of current research and development will be given, with a focus on the role of non-invasive medical devices to produce targeted and optimized drug delivery via local, systemic and nose-to-brain routes. Lastly, the talk will discuss how emerging medical devices can also serve to substantially improve the well-known problem of treatment and medicine adherence, which itself is a $300 billion per year problem and poor adherence will continue to impede even the greatest of advancements in drug delivery and nanomedicine if the problem is not resolved.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 8 May 2017
Targeted drug delivery system of 5 - Fluorouracil with recombinant epidermal growth factor for brain tumor
Perspective · 30 Oct 2024
Advancements in Targeted Drug Delivery Systems: Optimizing Therapeutic Efficacy and Reducing Side Effects
Research article · 9 Mar 2015
PLASMA GLYCOPROTEIN INHIBITORS AS A NEW TARGET FOR OPTIMAL DRUG DELIVERY
Article · 2013
Preparation and Optimization of Nanoemulsions for targeting Drug Delivery
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectPharmaceutical Sciences
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Don Turner”
